文献速递精神分裂症与精神病性障碍

三角互证GALENOS关于痕量胺相关受体1(TAAR1)激动剂治疗精神病的活系统综述证据

Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.
PubMed 文献 · Br J Psychiatry · 2024-12-23

本研究属于GALENOS项目,通过多学科专家(含经验亲历者)三角互证动物与人类活系统综述,评估TAAR1激动剂治疗精神病的效果。动物数据提示潜在抗精神病作用;人类研究中乌洛他隆和拉米他隆与安慰剂在改善急性精神分裂症总体症状上差异不大(4项研究,n=1291,SMD 0.15,95%CI -0.05至0.34),拉米他隆效果不及利培酮(1项研究,n=156,SMD=-0.53,95%CI -0.86至-0.20),副作用特征较现有抗精神病药有利。

要点

  • 动物数据提示TAAR1激动剂可减少致精神病药物诱导的活动增多,具潜在抗精神病效应。
  • 乌洛他隆和拉米他隆对比安慰剂改善急性精神分裂症总体症状差异不大(SMD 0.15,95%CI -0.05至0.34)。
  • 拉米他隆效果不及利培酮(SMD=-0.53,95%CI -0.86至-0.20),TAAR1激动剂副作用特征较现有抗精神病药有利。

核心结论

  • 该国际三角互证评估了TAAR1激动剂治疗精神病的现有证据,并为未来研究和临床应用制定建议。

研究设计与样本

  • 本研究为GALENOS项目的一部分,由多学科专家(含经验亲历者)会议评估GALENOS首批共同产出的动物和人类活系统综述,进行三角互证。

主要发现

  • 动物数据提示潜在抗精神病效应,TAAR1激动剂减少致精神病药物处理诱导的活动增多。
  • 人类研究中乌洛他隆和拉米他隆对比安慰剂改善成人急性精神分裂症总体症状差异不大(4项研究,n=1291,SMD 0.15,95%CI -0.05至0.34)。
  • 乌洛他隆三期试验中观察到较大安慰剂反应。
  • 拉米他隆效果不及利培酮(1项研究,n=156,SMD=-0.53,95%CI -0.86至-0.20)。
  • TAAR1激动剂副作用特征较现有抗精神病药有利。

关键数值与推荐

  • 未来研究优先方向包括:使用更具转化效度的不同精神病动物模型;纳入认知和情感症状等更广泛结局的动物与人类研究;机制研究及其他潜在应用(如辅助治疗和长期结局)的探索。
  • 活系统综述未来迭代的建议包括:个体人类参与者数据的Meta分析;纳入使用不同方法学的研究;评估其他障碍和症状。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 更广泛的挑战包括难以评估偏倚风险、可重复性、动物模型向临床结局的转化和可解释性,以及人类数据缺乏个体和临床特征。
  • 研究将为一个由经验亲历专家领导的独立优先排序过程提供信息,以确定未来研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trace amine-associated receptor 1 (TAAR1) agonists offer a new approach, but there is uncertainty regarding their effects, exact mechanism of action and potential role in treating psychosis. AIMS: To evaluate the available evidence on TAAR1 agonists in psychosis, using triangulation of the output of living systematic reviews (LSRs) of animal and human studies, and provide recommendations for future research prioritisation. METHOD: This study is part of GALENOS (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis). In the triangulation process, a multidisciplinary group of experts, including those with lived experience, met and appraised the first co-produced living systematic reviews from GALENOS, on TAAR1 agonists. RESULTS: The animal data suggested a potential antipsychotic effect, as TAAR1 agonists reduced locomotor activity induced by pro-psychotic drug treatment. Human studies showed few differences for ulotaront and ralmitaront compared with placebo in improving overall symptoms in adults with acute schizophrenia (four studies, n = 1291 participants, standardised mean difference (SMD) 0.15, 95% CI -0.05 to 0.34). Large placebo responses were seen in ulotaront phase three trials. Ralmitaront was less efficacious than risperidone (one study, n = 156 participants, SMD = -0.53, 95% CI -0.86 to -0.20). The side-effect profile of TAAR1 agonists was favourable compared with existing antipsychotics. Priorities for future studies included (a) using different animal models of psychosis with greater translational validity; (b) animal and human studies with wider outcomes including cognitive and affective symptoms and (c) mechanistic studies and investigations of other potential applications, such as adjunctive treatments and long-term outcomes. Recommendations for future iterations of the LSRs included (a) meta-analysis of individual human participant data, (b) including studies that used different methodologies and (c) assessing other disorders and symptoms. CONCLUSIONS: This co-produced, international triangulation examined the available evidence and developed recommendations for future research and clinical applications for TAAR1 agonists in psychosis. Broader challenges included difficulties in assessing the risk of bias, reproducibility, translation and interpretability of animal models to clinical outcomes, and a lack of individual and clinical characteristics in the human data. The research will inform a separate, independent prioritisation process, led by lived experience experts, to prioritise directions for future research.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Smith KA, Boyce N, Chevance A, et al. Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis. Br J Psychiatry. 2024. PMID: 39710623. doi:10.1192/bjp.2024.237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。